GLENMARK Glenmark Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Glenmark Pharma delivered a strong Q3 FY26, with consolidated revenue growing 15.1% Y-o-Y to INR39,006 million, driven by robust performance in India, North America, and Europe. The company maintained a 23% EBITDA margin and is on track to achieve net debt zero by March '26. Key innovative products like RYALTRIS continue to scale, and the Monroe facility's FDA clearance is a significant positive for the US business, despite a long breakeven timeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 4.8%, net profit down 31.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 −42% | 2,360 +5% |
| EBITDA | 779 | 494 | 341 | 728 | -178 −123% | 496 +0% |
| Net profit | 595 | 414 | 148 | 330 | -739 −224% | 282 −32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
